secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADAPTIN BIO, INC. (APTN)
CIK:        0001938571
Form:       8-K/A
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001213900-25-031875
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt
--------------------------------------------------------------------------------

- Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.
- Cash of only $34K as of Dec 31, 2024; accumulated deficit $4.12M.
- Auditor expresses substantial doubt about ability to continue as going concern.
- Convertible notes payable of $1.25M and derivative liability of $545K recorded.
- Deferred equity issuance costs of $194K reflect planned capital raise; management cites need for additional funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025031875/0001213900-25-031875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025031875/ea0238102-8ka1_adaptin.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-031875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer